Pirfenidone (PFD) is a new pyridone compound with a broad-spectrum anti-fibrosis effect, which can prevent and reverse the formation of fibrosis and scars; it was marketed by Shiono Yoshihide in 2008 and has been obtained. Approved by the U.S. Food and Drug Administration, it is the first drug that has proven to have a Chemicalbook effect on idiopathic pulmonary fibrosis (IPF) through a repeated, randomized, placebo-controlled Phase III clinical trial; and the drug is in the renal interstitium Fibrosis, liver fibrosis and other fibrotic diseases are also effective; at the same time, it is also effective in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I multiple neurofibroma, and adolescents. Type I multiple neurofibroma and plexiform neurofibroma, diabetes with kidney disease, phase II clinical studies of uterine leiomyoma have been widely used.
Pirfenidone can inhibit the uterine flesh tumour cells and leiomyoma cells proliferation. Pirfenidone can inhibit the TGF - beta - 1 inducing fibroblast collagen formation. Inhibition , FGF and TGF - beta - 1 inducing fibroblast proliferation. In hamster model, pirfenidone, taken by mouth, that can the prevention and treatment of pulmonary fibrosis induced by bleomycin. Pirfenidone can prevent the sclerosing peritonitis in rats induced by chemical, can also be keloid grafting for the treatment of nude mice. Pirfenidone 0.01 1 mg/ml can suppress the matrix and dose dependent manner serum stimulate uterine fibroids and leiomyoma cell DNA synthesis, the compound has no cytotoxic effect, has no effect on collagen mRNA level also. Pirfenidone in hamster pulmonary fibrosis model can reduce the disease before the collagen I mRNA level enhancement,reduce the level of the lung hydroxyproline and malondialadehyde and lung preserved ammoni a acyl hydroxylase activity.